Literature DB >> 9868646

The incidence and spectrum of AIDS-defining illnesses in persons treated with antiretroviral drugs.

D M Forrest1, E Seminari, R S Hogg, B Yip, J Raboud, L Lawson, P Phillips, M T Schechter, M V O'Shaughnessy, J S Montaner.   

Abstract

The incidence and spectrum of primary AIDS-defining illnesses in human immunodeficiency virus-positive patients receiving antiretroviral drugs may have changed since the introduction of newer antiretroviral agents. We performed a retrospective analysis of patients enrolled in the British Columbia Drug Treatment Program who were ever prescribed antiretroviral drugs between 1 January 1994 and 31 December 1996. Rates were calculated on a 6-month basis. There were 344 AIDS cases diagnosed among 2,533 participants between 1994 and 1996. The incidence of primary AIDS diseases decreased from 1994 to 1996, with a sharp decline in 1995 and 1996. There was no statistically significant change in the incidence of primary AIDS diagnoses relative to one another, and Pneumocystis carinii pneumonia and Kaposi's sarcoma remain the most common AIDS index diagnoses. In patients receiving antiretroviral therapy in the modern era, the incidence of AIDS-defining illnesses has decreased substantially, but the spectrum of AIDS-defining illnesses remains unchanged.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9868646     DOI: 10.1086/515030

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN: 1058-4838            Impact factor:   9.079


  24 in total

1.  Etiology and evaluation of diarrhea in AIDS:a global perspective at the millennium.

Authors:  C Mel Wilcox
Journal:  World J Gastroenterol       Date:  2000-04       Impact factor: 5.742

2.  Role of human cytomegalovirus genotype polymorphisms in AIDS patients with cytomegalovirus retinitis.

Authors:  Jens-Uwe Vogel; Jürgen Otte; Frank Koch; Hermann Gümbel; Hans Wilhelm Doerr; Jindrich Cinatl
Journal:  Med Microbiol Immunol       Date:  2012-06-06       Impact factor: 3.402

3.  Recent Developments in Epidemiology, Treatment, and Diagnosis of Tuberculosis.

Authors: 
Journal:  Curr Infect Dis Rep       Date:  1999-04       Impact factor: 3.725

Review 4.  Human cytomegalovirus resistance to antiviral drugs.

Authors:  C Gilbert; G Boivin
Journal:  Antimicrob Agents Chemother       Date:  2005-03       Impact factor: 5.191

5.  Changes in the pattern of respiratory diseases necessitating hospitalization of HIV-infected patients since the advent of highly active antiretroviral therapy.

Authors:  Véronique Dufour; Jacques Cadranel; Marie Wislez; Armelle Lavole; Emmanuel Bergot; Antoine Parrot; Pierre Rufat; Charles Mayaud
Journal:  Lung       Date:  2004       Impact factor: 2.584

6.  New reporter cell line to evaluate the sequential emergence of multiple human cytomegalovirus mutations during in vitro drug exposure.

Authors:  C Gilbert; G Boivin
Journal:  Antimicrob Agents Chemother       Date:  2005-12       Impact factor: 5.191

7.  Pneumocystis carinii activates the NF-kappaB signaling pathway in alveolar epithelial cells.

Authors:  Jing Wang; Francis Gigliotti; Sanjay Maggirwar; Carl Johnston; Jacob N Finkelstein; Terry W Wright
Journal:  Infect Immun       Date:  2005-05       Impact factor: 3.441

8.  The changing face of AIDS-related opportunism: cryptococcosis in the highly active antiretroviral therapy (HAART) era. Case reports and literature review.

Authors:  R Manfredi; F Pieri; S A Pileri; F Chiodo
Journal:  Mycopathologia       Date:  1999-11       Impact factor: 2.574

Review 9.  The changing epidemiology of HIV infection: new challenges for HIV palliative care.

Authors:  P Easterbrook; J Meadway
Journal:  J R Soc Med       Date:  2001-09       Impact factor: 5.344

10.  Disparities in HIV treatment and physician attitudes about delaying protease inhibitors for nonadherent patients.

Authors:  Mitchell D Wong; William E Cunningham; Martin F Shapiro; Ronald M Andersen; Paul D Cleary; Naihua Duan; Hong Hu Liu; Ira B Wilson; Bruce E Landon; Neil S Wenger
Journal:  J Gen Intern Med       Date:  2004-04       Impact factor: 5.128

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.